Alector, Inc. announced that its experimental therapy latozinemab failed to meet primary efficacy and safety endpoints in a ...

A new Northwestern University study using patient nervous tissue and lab-grown human neurons has uncovered how a key disease ...

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in Alzheimer's last November. On latozinemab for frontotemporal dementia, Alector was ...